S&P 500   3,379.88 (+1.39%)
DOW   27,921.35 (+0.85%)
QQQ   271.50 (+2.38%)
AAPL   449.76 (+2.80%)
MSFT   208.91 (+2.72%)
FB   260.71 (+1.79%)
GOOGL   1,505.20 (+1.67%)
AMZN   3,155.67 (+2.43%)
NVDA   454.73 (+4.78%)
CGC   17.40 (+2.65%)
BABA   255.51 (+2.85%)
TSLA   1,527.24 (+11.12%)
GE   6.61 (-1.78%)
MU   48.33 (+1.19%)
AMD   82.24 (+6.97%)
T   30.12 (-0.26%)
F   7.06 (-2.35%)
ACB   9.92 (-1.00%)
GILD   68.86 (+1.12%)
NFLX   479.79 (+2.75%)
DIS   130.63 (+0.11%)
BAC   26.47 (-1.67%)
BA   174.25 (-3.26%)
S&P 500   3,379.88 (+1.39%)
DOW   27,921.35 (+0.85%)
QQQ   271.50 (+2.38%)
AAPL   449.76 (+2.80%)
MSFT   208.91 (+2.72%)
FB   260.71 (+1.79%)
GOOGL   1,505.20 (+1.67%)
AMZN   3,155.67 (+2.43%)
NVDA   454.73 (+4.78%)
CGC   17.40 (+2.65%)
BABA   255.51 (+2.85%)
TSLA   1,527.24 (+11.12%)
GE   6.61 (-1.78%)
MU   48.33 (+1.19%)
AMD   82.24 (+6.97%)
T   30.12 (-0.26%)
F   7.06 (-2.35%)
ACB   9.92 (-1.00%)
GILD   68.86 (+1.12%)
NFLX   479.79 (+2.75%)
DIS   130.63 (+0.11%)
BAC   26.47 (-1.67%)
BA   174.25 (-3.26%)
S&P 500   3,379.88 (+1.39%)
DOW   27,921.35 (+0.85%)
QQQ   271.50 (+2.38%)
AAPL   449.76 (+2.80%)
MSFT   208.91 (+2.72%)
FB   260.71 (+1.79%)
GOOGL   1,505.20 (+1.67%)
AMZN   3,155.67 (+2.43%)
NVDA   454.73 (+4.78%)
CGC   17.40 (+2.65%)
BABA   255.51 (+2.85%)
TSLA   1,527.24 (+11.12%)
GE   6.61 (-1.78%)
MU   48.33 (+1.19%)
AMD   82.24 (+6.97%)
T   30.12 (-0.26%)
F   7.06 (-2.35%)
ACB   9.92 (-1.00%)
GILD   68.86 (+1.12%)
NFLX   479.79 (+2.75%)
DIS   130.63 (+0.11%)
BAC   26.47 (-1.67%)
BA   174.25 (-3.26%)
S&P 500   3,379.88 (+1.39%)
DOW   27,921.35 (+0.85%)
QQQ   271.50 (+2.38%)
AAPL   449.76 (+2.80%)
MSFT   208.91 (+2.72%)
FB   260.71 (+1.79%)
GOOGL   1,505.20 (+1.67%)
AMZN   3,155.67 (+2.43%)
NVDA   454.73 (+4.78%)
CGC   17.40 (+2.65%)
BABA   255.51 (+2.85%)
TSLA   1,527.24 (+11.12%)
GE   6.61 (-1.78%)
MU   48.33 (+1.19%)
AMD   82.24 (+6.97%)
T   30.12 (-0.26%)
F   7.06 (-2.35%)
ACB   9.92 (-1.00%)
GILD   68.86 (+1.12%)
NFLX   479.79 (+2.75%)
DIS   130.63 (+0.11%)
BAC   26.47 (-1.67%)
BA   174.25 (-3.26%)
Log in

NASDAQ:EIDXEidos Therapeutics News Headlines

$42.49
+0.26 (+0.62 %)
(As of 08/12/2020 01:47 PM ET)
Add
Compare
Today's Range
$41.93
Now: $42.49
$42.82
50-Day Range
$40.10
MA: $45.88
$51.41
52-Week Range
$28.39
Now: $42.49
$66.56
Volume792 shs
Average Volume104,553 shs
Market Capitalization$1.64 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.38

Headlines

Eidos Therapeutics (NASDAQ EIDX) News Headlines

Source:
DateHeadline
Eidos Therapeutics (NASDAQ:EIDX) Downgraded by BidaskClub to "Sell"Eidos Therapeutics (NASDAQ:EIDX) Downgraded by BidaskClub to "Sell"
marketbeat.com - August 1 at 1:27 AM
Eidos Therapeutics Inc (NASDAQ:EIDX) Expected to Announce Earnings of -$0.61 Per ShareEidos Therapeutics Inc (NASDAQ:EIDX) Expected to Announce Earnings of -$0.61 Per Share
www.americanbankingnews.com - July 25 at 4:08 AM
Eidos Therapeutics Inc (NASDAQ:EIDX) Given Consensus Recommendation of "Hold" by AnalystsEidos Therapeutics Inc (NASDAQ:EIDX) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - July 19 at 3:14 AM
Hedge Funds Are Dumping Eidos Therapeutics, Inc. (EIDX)Hedge Funds Are Dumping Eidos Therapeutics, Inc. (EIDX)
finance.yahoo.com - July 5 at 6:23 PM
Eidos Therapeutics (EIDX) Looks Good: Stock Adds 6.4% in SessionEidos Therapeutics (EIDX) Looks Good: Stock Adds 6.4% in Session
finance.yahoo.com - July 1 at 9:35 AM
Eidos Therapeutics, Inc. Common Stock (EIDX) Insider Activity | NasdaqEidos Therapeutics, Inc. Common Stock (EIDX) Insider Activity | Nasdaq
www.nasdaq.com - May 21 at 12:56 AM
Notable Two Hundred Day Moving Average Cross - EIDXNotable Two Hundred Day Moving Average Cross - EIDX
www.nasdaq.com - April 30 at 5:33 PM
Sell-siders cut views on Tivity Health after ugly Q4Sell-siders cut views on Tivity Health after ugly Q4
seekingalpha.com - February 20 at 9:29 AM
Noteworthy Wednesday Option Activity: AKAM, EIDX, TGTNoteworthy Wednesday Option Activity: AKAM, EIDX, TGT
www.nasdaq.com - February 19 at 5:58 PM
Vertex (VRTX) Hits 52-Week High, Can the Run Continue?Vertex (VRTX) Hits 52-Week High, Can the Run Continue?
finance.yahoo.com - February 5 at 10:43 AM
Eidos Therapeutics Becomes Oversold (EIDX)Eidos Therapeutics Becomes Oversold (EIDX)
www.nasdaq.com - January 29 at 1:30 PM
Eidos Therapeutics, Inc. (EIDX): Are Hedge Funds Right About This Stock?Eidos Therapeutics, Inc. (EIDX): Are Hedge Funds Right About This Stock?
finance.yahoo.com - December 12 at 6:16 PM
Eidos Therapeutics, Inc. (EIDX) Moves to Buy: Rationale Behind the UpgradeEidos Therapeutics, Inc. (EIDX) Moves to Buy: Rationale Behind the Upgrade
finance.yahoo.com - November 18 at 10:29 AM
Eidos Therapeutics EPS of $0.18Eidos Therapeutics EPS of $0.18
seekingalpha.com - October 31 at 5:28 PM
BridgeBio Calls Off Its Acquisition Offer for Eidos TherapeuticsBridgeBio Calls Off Its Acquisition Offer for Eidos Therapeutics
www.nasdaq.com - October 20 at 9:03 AM
Eidos Therapeutics, Inc.Eidos Therapeutics, Inc.
www.fool.com - October 10 at 10:45 PM
Eidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy at the AHA 2019 Scientific Sessions in a Late-Breaking Featured Science Oral PresentationEidos Therapeutics to Present Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study of AG10 in Patients with TTR Amyloid Cardiomyopathy at the AHA 2019 Scientific Sessions in a Late-Breaking Featured Science Oral Presentation
finance.yahoo.com - September 30 at 5:21 PM
Eidos Therapeutics to Present at the 2019 Cantor Global Healthcare ConferenceEidos Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
finance.yahoo.com - September 19 at 7:11 PM
EIDOS THERAPEUTICS (EIDX) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Eidos Therapeutics, Inc. for Potential Securities Violations and Breach of Fiduciary DutyEIDOS THERAPEUTICS (EIDX) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Eidos Therapeutics, Inc. for Potential Securities Violations and Breach of Fiduciary Duty
finance.yahoo.com - September 17 at 4:00 PM
Eidos rejects BridgeBio bid for sharesEidos rejects BridgeBio bid for shares
seekingalpha.com - September 13 at 9:54 AM
Alexion and BridgeBio Announce Japanese License Agreement for Eidos’ Transthyretin Amyloidosis (ATTR) Investigational MedicineAlexion and BridgeBio Announce Japanese License Agreement for Eidos’ Transthyretin Amyloidosis (ATTR) Investigational Medicine
www.marketwatch.com - September 9 at 10:18 AM
Alexion inks deal for ATTR investigational medicine in JapanAlexion inks deal for ATTR investigational medicine in Japan
seekingalpha.com - September 9 at 10:18 AM
Kaskela Law LLC Announces Shareholder Investigation of Eidos Therapeutics, Inc. and Encourages Investors to Contact the Firm – EIDXKaskela Law LLC Announces Shareholder Investigation of Eidos Therapeutics, Inc. and Encourages Investors to Contact the Firm – EIDX
finance.yahoo.com - September 3 at 12:47 PM
A 29-year-old exec who worked on 2019s biggest biotech IPO told us the 2 key lessons that made it a successA 29-year-old exec who worked on 2019's biggest biotech IPO told us the 2 key lessons that made it a success
www.businessinsider.com - August 23 at 12:04 PM
Kaskela Law LLC Announces Shareholder Investigation of Eidos Therapeutics, Inc. - EIDXKaskela Law LLC Announces Shareholder Investigation of Eidos Therapeutics, Inc. - EIDX
finance.yahoo.com - August 14 at 11:08 AM
8 Biotechs Being Choked by Short Sellers8 Biotechs Being Choked by Short Sellers
247wallst.com - August 13 at 9:05 PM
Little over year after IPO, biotech's majority owner wants to buy it allLittle over year after IPO, biotech's majority owner wants to buy it all
finance.yahoo.com - August 12 at 8:46 PM
Eidos receives non-binding bid from BridgeBio for remaining sharesEidos receives non-binding bid from BridgeBio for remaining shares
seekingalpha.com - August 12 at 12:22 PM
Eidos Therapeutics Confirms Receipt of Non-Binding Proposal from BridgeBio Pharma to Acquire SharesEidos Therapeutics Confirms Receipt of Non-Binding Proposal from BridgeBio Pharma to Acquire Shares
finance.yahoo.com - August 12 at 12:22 PM
Eidos Therapeutics Reports Second Quarter 2019 Financial ResultsEidos Therapeutics Reports Second Quarter 2019 Financial Results
finance.yahoo.com - August 1 at 9:01 PM
Are Investors Undervaluing Eidos Therapeutics, Inc. (NASDAQ:EIDX) By 34%?Are Investors Undervaluing Eidos Therapeutics, Inc. (NASDAQ:EIDX) By 34%?
finance.yahoo.com - July 1 at 11:25 AM
Is Eidos Therapeutics, Inc. (NASDAQ:EIDX) Trading At A 34% Discount?Is Eidos Therapeutics, Inc. (NASDAQ:EIDX) Trading At A 34% Discount?
finance.yahoo.com - July 1 at 11:25 AM
BridgeBio Seeks $225 Million In U.S. IPOBridgeBio Seeks $225 Million In U.S. IPO
seekingalpha.com - June 21 at 3:52 PM
Eidos Therapeutics to Present at the 2019 BMO Prescriptions for Success Healthcare ConferenceEidos Therapeutics to Present at the 2019 BMO Prescriptions for Success Healthcare Conference
finance.yahoo.com - June 18 at 6:13 PM
Gene Therapy Parent BridgeBio Set to Go PublicGene Therapy Parent BridgeBio Set to Go Public
finance.yahoo.com - May 31 at 11:46 AM
3 Peninsula biotech IPOs show off diversity of targets, seek to raise more than $400M3 Peninsula biotech IPOs show off diversity of targets, seek to raise more than $400M
www.bizjournals.com - May 28 at 11:40 AM
Did Hedge Funds Drop The Ball On Eidos Therapeutics, Inc. (EIDX) ?Did Hedge Funds Drop The Ball On Eidos Therapeutics, Inc. (EIDX) ?
finance.yahoo.com - May 10 at 12:01 PM
Eidos Therapeutics Reports First Quarter 2019 Financial ResultsEidos Therapeutics Reports First Quarter 2019 Financial Results
www.nasdaq.com - May 8 at 12:07 PM
Eidos Therapeutics misses by $0.01Eidos Therapeutics misses by $0.01
seekingalpha.com - May 8 at 12:07 PM
Biotech News Recap: Catalyst Pharmaceuticals Hit By Surprise From FDA, But Should Recover With Coming CatalystsBiotech News Recap: Catalyst Pharmaceuticals Hit By Surprise From FDA, But Should Recover With Coming Catalysts
seekingalpha.com - May 7 at 3:53 PM
Eidos Therapeutics Reports Fourth Quarter and Year-End 2018 Financial ResultsEidos Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results
finance.yahoo.com - April 15 at 8:54 AM
Eidos Therapeutics Inc.Eidos Therapeutics Inc.
www.barrons.com - April 12 at 2:00 PM
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Eidos Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmINVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Eidos Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - April 5 at 3:53 PM
RM LAW Announces an Investigation of Eidos Therapeutics, Inc.RM LAW Announces an Investigation of Eidos Therapeutics, Inc.
finance.yahoo.com - April 5 at 3:53 PM
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Eidos Therapeutics, Inc. (EIDX) InvestigationShareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Eidos Therapeutics, Inc. (EIDX) Investigation
finance.yahoo.com - April 4 at 11:52 AM
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces It is Investigating Claims against Eidos Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmIMPORTANT INVESTOR ALERT: The Schall Law Firm Announces It is Investigating Claims against Eidos Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - April 2 at 4:18 PM
Eidos to restate 2018 financialsEidos to restate 2018 financials
seekingalpha.com - April 2 at 11:30 AM
Eidos Therapeutics Investigated by Block & Leviton LLP For Violations of Federal Securities LawsEidos Therapeutics Investigated by Block & Leviton LLP For Violations of Federal Securities Laws
finance.yahoo.com - April 2 at 11:30 AM
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Eidos Therapeutics, Inc. – EIDXEQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Eidos Therapeutics, Inc. – EIDX
finance.yahoo.com - April 2 at 11:30 AM
INVESTIGATION ALERT: The Schall Law Firm Announces It is Investigating Claims against Eidos Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmINVESTIGATION ALERT: The Schall Law Firm Announces It is Investigating Claims against Eidos Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - April 2 at 11:30 AM
Bragar Eagel & Squire, P.C. is Investigating Eidos Therapeutics, Inc. (EIDX) on Behalf of Stockholders and Encourages EIDX Investors to Contact the FirmBragar Eagel & Squire, P.C. is Investigating Eidos Therapeutics, Inc. (EIDX) on Behalf of Stockholders and Encourages EIDX Investors to Contact the Firm
finance.yahoo.com - April 2 at 11:30 AM
This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.